Aβ1-15 is less immunogenic than Aβ1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting"

Vaccine

Volumn 21, Issue 17-18, 2003, Pages 2197-2206

  Leverone, Jodi F ^a   Spooner, Edward T ^a   Lehman, Herman K ^b   Clements, John D ^c   Lemere, Cynthia A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HAMILTON COLLEGE   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Heat labile enterotoxin; LT; Vaccine; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; ENTEROTOXIN; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; ISOPROTEIN; PROTEIN ANTIBODY;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; WILD TYPE;

EID: 0037449117     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00754-5     Document Type: Article

References (22)

1. Dickson D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56(4):1997;321-339.
2. Naslund J., Haroutunian V., Mohs R.et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA. 283:2000;1571-1577.
3. Schenk D., Barbour R., Dunn W.et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
4. Weiner H.L., Lemere C.A., Maron R.et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in mouse model of Alzheimer's disease. Ann. Neurol. 48(4):2000;567-579.
5. Lemere C.A., Maron R., Spooner E.et al. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. 920:2000;328-331.
6. Janus C., Pearson J., McLaurin J.et al. Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature. 408(6815):2000;979-982.
7. Morgan D., Diamond D.M., Gottschall P.E.et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):2000;982-985.
8. Lemere C.A., Spooner E.T., Leverone J.F., Mori C., Clements J.D. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol. Aging. 23(6):2002;991-1000.
9. Del Giudice G., Pizza M., Rappuoli R. Mucosal delivery of vaccines. Methods. 19(1):1999;148-155.
10. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 1983;510-50.
11. Rappuoli R., Pizza M., Deuce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 20:1999;493-500.
12. Sixma T.K., Pronk S.E., Kalk K.H.et al. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature. 351:1991;371-377.
13. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63(5):1995;1617-1623.
14. Cardenas-Freytag L., Cheng E., Mayeux P., Domer J.E., Clements J.D. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systematic candidiasis. Infect. Immun. 67(2):1999;826-833.
15. Chong C., Friberg M., Clements J.D. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine. 16:1998;732-740.
16. Morris C.B., Cheng E., Thanawastien A., Cardenas-Freytag L., Clements J.D. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine. 18:2000;1944-1951.
17. Gluck U., Gebbers J.-O., Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73(9):1999;7780-7786.
18. Kotloff K.L., Sztein M.B., Wasserman S.S., Losonsky G.A., DiLorenzo S.C., Walker R.I. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69(6):2001;3581-3590.
19. Lemere C., Blustzjan J., Yamguchi H., Wisniewski T., Saido T., Selkoe D. Sequence of deposition of heterogenous amyloid p-peptides and Apo E in Down's syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3:1996;16-32.
20. Stolzner S.E., Grenfell T.J., Mori C.et al. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am. J. Pathol. 156(2):2000;489-499.
21. Bard F., Cannon C., Barbour R.et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8):1998;916-919.
22. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J., Paul S., Holtzman D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8850-8855.